Search

Your search keyword '"Ewa Wierzbicka-Hainaut"' showing total 8 results
Start Over Author "Ewa Wierzbicka-Hainaut"
8 results on '"Ewa Wierzbicka-Hainaut"'

1. Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis

Author

Julien Rossignol, Sophie Georgin-Lavialle, Danielle Canioni, Omer Beganovic, Chantal Brouzes, Olivier Fain, Maël Heiblig, Clément Gourguechon, Philippe Guilpain, Cristina Bulai-Livideanu, Stéphane Barete, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Catharina Chatain, Ghandi Damaj, Thomas Ballul, Celine Greco, Laura Polivka, Laurent Frenzel, Cécile Meni, Hassiba Bouktit, Dina Benabou, Clotilde Devin, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Thierry Jo Molina, Julie Bruneau, Rose-Marie Javier, Fabien Pelletier, Florence Castelain, Frederique Retornaz, Quentin Cabrera, Patricia Zunic, Marie Pierre Gourin, Ewa Wierzbicka-Hainaut, Jean François Viallard, Christian Lavigne, Cyrille Hoarau, Isabelle Durieu, Sophie Dimicoli-Salazar, Jose Miguel Torregrosa-Diaz, Audrey Duval, Nicolas Garcelon, Jeremie Lespinasse, Angèle Soria, Yannick Chantran, Michel Arock, Christine Bodemer, Olivier Lortholary, Vahid Asnafi, Olivier Hermine, and Ludovic Lhermitte

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

2. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)

Author

David Tougeron, Sheik Emambux, Laure Favot, Thierry Lecomte, Ewa Wierzbicka-Hainaut, Mahtab Samimi, Eric Frouin, Nicolas Azzopardi, Jocelyn Chevrier, Laura Serres, Julie Godet, Pierre Levillain, Gilles Paintaud, Aurélie Ferru, Laetitia Rouleau, Adriana Delwail, Christine Silvain, Jean-Pierre Tasu, Franck Morel, Stéphanie Ragot, and Jean-Claude Lecron

Subjects
skin toxicity, cetuximab, cytokines, inflammatory factors, monoclonal antibodies, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Anti-epidermal growth factor receptor (EGFR) monoclonal antibody is a standard treatment of metastatic colorectal cancer (mCRC) and its most common adverse effect is a papulopustular acneiform rash. The aim of the CUTACETUX study was to characterize the skin inflammatory response associated with this rash and its relation to treatment efficacy. This prospective study included patients with mCRC treated with first-line chemotherapy plus cetuximab. Patients underwent skin biopsies before the initiation of cetuximab (D0) and before the third infusion (D28), one in a rash zone and one in an unaffected zone. Expression of Th17-related cytokines (IL-17A, IL-21, IL-22), antimicrobial peptides (S100A7 and BD-2), innate response-related cytokines (IL-1β, IL-6, TNF-α and OSM), T-reg-related cytokines (IL-10 and TGF-β), Th1-related cytokine (IFN-γ), Th2-related cytokine (IL-4), Thymic stromal lymphopoietin and keratinocyte-derived cytokines (IL-8, IL-23 and CCL20) were determined by RT-PCR. Twenty-seven patients were included. Levels of most of the cytokines increased at D28 in the rash zone compared to D0. No significant association was observed between variations of cytokines levels and treatment response in the rash zone and only the increase of IL-4 (p = .04) and IL-23 (p = .02) levels between D0 and D28 in the unaffected zone was significantly associated with treatment response. Increased levels of IL-8 (p = .02), BD-2 (p = .02), IL-1β (p = .004) and OSM (p = .02) in the rash zone were associated with longer progression-free survival. Expression of Th2-related and keratinocyte-derived cytokines in the skin was associated with anti-EGFR efficacy. If this inflammatory signature can explain the rash, the exact mechanism by which these cytokines are involved in anti-EGFR tumor response remains to be studied.

Published
2020
Full Text
View/download PDF

3. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas

Author

Adèle de Masson, Marie Beylot-Barry, Jean-David Bouaziz, Régis Peffault de Latour, François Aubin, Sylvain Garciaz, Michel d’Incan, Olivier Dereure, Stéphane Dalle, Anne Dompmartin, Felipe Suarez, Maxime Battistella, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Henri Adamski, Pauline Brice, Sylvie François, Séverine Lissandre, Pascal Turlure, Ewa Wierzbicka-Hainaut, Eolia Brissot, Rémy Dulery, Sophie Servais, Aurélie Ravinet, Reza Tabrizi, Saskia Ingen-Housz-Oro, Pascal Joly, Gérard Socié, Martine Bagot, and French Study Group on Cutaneous Lymphomas and Société Française de Greffe de Moëlle et Thérapie Cellulaire

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

The treatment of advanced stage primary cutaneous T-cell lymphomas remains challenging. In particular, large-cell transformation of mycosis fungoides is associated with a median overall survival of two years for all stages taken together. Little is known regarding allogeneic hematopoietic stem cell transplantation in this context. We performed a multicenter retrospective analysis of 37 cases of advanced stage primary cutaneous T-cell lymphomas treated with allogeneic stem cell transplantation, including 20 (54%) transformed mycosis fungoides. Twenty-four patients (65%) had stage IV disease (for mycosis fungoides and Sézary syndrome) or disseminated nodal or visceral involvement (for non-epidermotropic primary cutaneous T-cell lymphomas). After a median follow up of 29 months, 19 patients experienced a relapse, leading to a 2-year cumulative incidence of relapse of 56% (95%CI: 0.38–0.74). Estimated 2-year overall survival was 57% (95%CI: 0.41–0.77) and progression-free survival 31% (95%CI: 0.19–0.53). Six of 19 patients with a post-transplant relapse achieved a subsequent complete remission after salvage therapy, with a median duration of 41 months. A weak residual tumor burden before transplantation was associated with increased progression-free survival (HR=0.3, 95%CI: 0.1–0.8; P=0.01). The use of antithymocyte globulin significantly reduced progression-free survival (HR=2.9, 95%CI: 1.3–6.2; P=0.01) but also transplant-related mortality (HR=10−7, 95%CI: 4.10−8−2.10−7; P

Published
2014
Full Text
View/download PDF

4. Efficacy of imiquimod in the management of lentigo maligna

Author

Marie Daude, Monica Dinulescu, Jean‐Michel Nguyen, Hervé Maillard, Florence Le Duff, Laurent Machet, Marie Beylot‐Barry, Delphine Legoupil, Ewa Wierzbicka‐Hainaut, Christophe Bedane, Marie Thérèse Leccia, Sébastien Debarbieux, Nicolas Meyer, Sandrine Monestier, Guido Bens, Marc G. Denis, Celine Bossard, Beatrice Vergier, Amir Khammari, and Brigitte Dréno

Subjects
Infectious Diseases, Dermatology
Published
2023

5. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study

Author

Adèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Jean-Baptiste Mear, Stéphane Dalle, Michel d'Incan, Saskia Ingen-Housz-Oro, Corentin Orvain, Julie Abraham, Olivier Dereure, Amandine Charbonnier, Jérôme Cornillon, Christine Longvert, Stéphane Barete, Serge Boulinguez, Ewa Wierzbicka-Hainaut, François Aubin, Marie-Thérèse Rubio, Marc Bernard, Aline Schmidt-Tanguy, Roch Houot, Anne Pham-Ledard, David Michonneau, Pauline Brice, Hélène Labussière-Wallet, Jean-David Bouaziz, Florent Grange, Hélène Moins-Teisserenc, Katayoun Jondeau, Laurence Michel, Samia Mourah, Maxime Battistella, Etienne Daguindau, Michael Loschi, Alexandra Picard, Nathalie Franck, Natacha Maillard, Anne Huynh, Stéphanie Nguyen, Ambroise Marçais, Guillaume Chaby, Patrice Ceballos, Yannick Le Corre, Sébastien Maury, Jacques-Olivier Bay, Henri Adamski, Emmanuel Bachy, Edouard Forcade, Gérard Socié, Martine Bagot, Sylvie Chevret, and Régis Peffault de Latour

Subjects
General Medicine
Published
2023

6. Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster Trial

Author

Diane Marcé, Floriane Le Vilain-Abraham, Morgiane Bridou, Gaelle Quéreux, Alain Dupuy, Thierry Lesimple, Yannick Le Corre, Ewa Wierzbicka-Hainaut, Delphine Legoupil, Philippe Célérier, Hervé Maillard, Laurent Machet, and Agnès Caille

Subjects
Cancer Research, Oncology, cluster randomized trial, melanoma, prevention, screening, intervention, medical skin examination, sun-related behaviors, first-degree relatives, high-risk population, familial
Abstract

Background: First-degree relatives (FDRs, defined as parents, children, and siblings) of melanoma patients are at a two-to-fivefold increased risk of developing melanoma themselves. FDRs are advised to perform self-skin examination (SSE) and annual medical total cutaneous examination (TCE) performed either by a dermatologist or a general practitioner, and to change their sun-related behavior. This advice is given orally to melanoma patients who are asked to relay the information to their FDRs. Objective: Our aim was to determine the impact of providing a tip sheet to melanoma patients intended to their first-degree relatives (FDRs) on early detection and sun-related behaviors in this group at increased risk of melanoma. Methods: A superiority, cluster-randomized trial was conducted at nine hospital centers. In the intervention group, dermatologists were asked to deliver to melanoma patients (index cases) the tip sheet and oral advice intended to their FDRs. The control group were asked to deliver the usual oral advice alone. The primary outcome was early detection of melanoma in FDRs with a medical TCE performed within one year after the first visit of the index case. Secondary outcomes were SSE and sun-related behaviors in FDRs. Results: A total of 48 index cases and 114 FDRS in the control group, 60 index cases and 166 FDRS in the intervention group were recruited. In the intervention group, 36.1% of FDRs performed a medical TCE as compared to 39.5% of FDRs in the control group (OR 0.9 [95% CI 0.5 to 1.5], p = 0.63). We did not find a between-group difference in SSE and sun-related behaviors. Conclusion: A tip sheet added to the usual oral advice did not increase medical TCE among FDRs of melanoma patients. Overall, the rate of TCE among FDRs was low. Research on other strategies is needed to increase melanoma detection in this population.

Published
2022

7. Effets des masques faciaux sur l’apparition ou l’exacerbation des dermatoses faciales au CHU de Poitiers : étude observationnelle monocentrique

Author

Alain Vaudel, Ewa Wierzbicka-Hainaut, Marie Masson-Regnault, Rodolphe Riviere, and Julie Paul

Subjects
Ocean Engineering, Safety, Risk, Reliability and Quality
Abstract

Introduction Pendant la pandemie de COVID-19, le port d’un masque facial etait fortement recommande dans de nombreux pays et obligatoire dans les etablissements de sante. Quelques donnees sont disponibles sur la tolerance des differents types de masque, mais elles ne concernent pas les masques en tissu et sont peu nombreuses. Nous avons donc realise une enquete, dont l’objectif etait d’evaluer la prevalence des dermatoses faciales liees au masque facial au CHU de Poitiers. Materiel et methodes Nous avons realise une etude observationnelle monocentrique aupres de l’ensemble du personnel administratif, paramedical et medical du CHU de Poitiers, entre le 26 novembre et le 5 decembre 2020. Le questionnaire, comportant des donnees demographiques (duree de port hebdomadaire, type de travail, presence ou non de dermatose faciale), a ete construit a l’aide de DragNSurvey® et envoye par mail. Resultats La prevalence des dermatoses sous masque (dermatoses inaugurales et dermatoses supplementaires chez les sujets ayant une dermatose faciale preexistante) etait de 53 % (34 % avant la periode de port du masque (p = 10−16)). L’âge moyen des sujets atteints de dermatose etait de 38,9 ans [± 10,3 ans], et l’âge moyen des sujets indemnes etait de 42,3 ans [± 11,3 ans] (p 20 h par semaine) par rapport aux durees les plus courtes ( 20 h et 64 % de dermatose pour une duree Discussion Notre etude met en evidence une prevalence elevee des dermatoses faciales de novo (53 %) lors d’une utilisation quotidienne des masques faciaux. Elle met aussi en evidence un fait nouveau : nous avons mis en evidence un risque moindre lie a l’utilisation des maques tissu par rapport aux masques chirurgicaux et FFP2. Le lien entre la duree hebdomadaire de port du masque, l’âge moyen plus jeune et la survenue des dermatoses est confirme.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results